Small molecule · developed by Heron Therapeutics
HTX-034 is a fixed-dose and individualized-dose combination of bupivacaine, aprepitant and meloxicam. It is studied in patients with bunions and postoperative pain.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04398329 | Phase 1/2 | Bunions | Completed | HRTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
BunionsPostoperative Pain
Updated Oct 18, 2026. Something wrong or missing? Report it on the HRTX page.
See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRTX catalysts and pipeline →